Abstract: A processing device (30, 710) for reducing scan traffic is provided. The processing device (30, 710) comprises one or more interfaces (32, 718) configured to transmit information to at least one register access interface (759, 761) and processing circuitry (34) configured to control the one or more interfaces. Further, the processing circuitry (34) is configured to obtain register parameters of at least one functional unit (760, 762) of a processing unit (750) and to generate an improved bulk register comprising the register parameters of the at least one functional unit.

Abstract: Provided is a perfusion culture method for CAR-T cells. The method comprises the following steps: 1) separating peripheral blood mononuclear cells from a single blood cell of a subject, and sorting the mononuclear cells to obtain T cells; 2) carrying out activation treatment on the separated T cells by using CD3/CD28 stimulation magnetic beads; 3) infecting the activated T cells by using a lentiviral vector; 4) carrying out perfusion culture on the lentivirus-infected T cells, and harvesting CAR-T cells, wherein the composition of a serum-free culture medium, which does not contain an animal-derived component, for culturing the CAR-T cells is: AIM-V+(3-9)% ISR; and the perfusion culture comprises the following stages: the first stage: when the cell density is (0.5-1.1)×106 cells/mL, the perfusion rate is A1, and/or the second stage: when the cell density is (1.

Abstract: A processing device (30, 710) for reducing scan traffic is provided. The processing device (30, 710) comprises one or more interfaces (32, 718) configured to transmit information to at least one register access interface (759, 761) and processing circuitry (34) configured to control the one or more interfaces. Further, the processing circuitry (34) is configured to obtain register parameters of at least one functional unit (760, 762) of a processing unit (750) and to generate an improved bulk register comprising the register parameters of the at least one functional unit.

Abstract: The present invention provides a test device for nucleic acid, including a sample treatment chamber, a sample reaction chamber and a test chamber which are disposed from top to bottom successively. The functions of sampling, nucleic acid purification, isothermal amplification and testing result reading by immunochromatography are integrated onto a device to prepare a simple and cute test device for nucleic acid; the device can achieve nucleic acid testing only by two rotations and can ensure that each sampling or reagent adding can reach the target area in a free falling way without any extra drainage facility. The present invention has lower costs, more convenient operation, high detection sensitivity, short time required in nucleic acid testing, and can be used for nucleic acid testing of various samples, such as human and animals.

Abstract: Methods and kits are provided for detecting and discriminating between immune quiescence and allograft rejections, such as T cell-mediated rejection and antibody-mediated rejection, using differential gene expression signatures alone or in combination with levels of transplant-derived cell-free nucleic acids.

Abstract: The present invention provides compositions and methods related to determining the severity of viral infections and identifying antiviral agents. In certain embodiments, the invention comprises determining the expression level of APOBEC-1 related proteins, where the expression level of APOBEC-1 related proteins is an indicator for disease severity and/or effectiveness of a potential antiviral agent. In one embodiment, the present invention provides for a method of screening for an antiviral agent.

Abstract: The present invention relates to a method of detecting immune enhancement of virus infectivity, a method of determining neutralization and immune enhancement of virus infectivity, a method of identifying a virus epitope that displays immune enhancement, a method of identifying a compound that modulates activity of an Fc receptor, and a method of identifying a compound that modulates intracellular signaling of an Fc receptor. DNA constructs, cells, and kits relating to these assays are also disclosed.

Abstract: The disclosure provides a tetravalent Dengue virus vaccine, and methods of inducing a immune response against a Flavivirus such as Dengue virus 1-4 using the vaccine. The disclosure also provides methods of making a vaccine by introducing into a host cell a transgene that encodes a protein comprising Dengue domain III polypeptides, or, by purified dill polypeptides specific for Dengue serotypes 1-4, Yellow Fever Virus, West Nile Virus, Japanese Encephalitis Virus, and Flaviviruses.

Abstract: The present invention relates to a method of interfering with dengue infection comprising interfering with dengue virus binding to a syndecan present on a cell targeted by dengue virus. The present invention further relates to treating a patient for dengue virus infection comprising administering to a patient, either having a dengue infection or a patient exposed to dengue infection, an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus. The present invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier, and an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus.

Abstract: The present invention relates to a method of detecting immune enhancement of virus infectivity, a method of determining neutralization and immune enhancement of virus infectivity, a method of identifying a virus epitope that displays immune enhancement, a method of identifying a compound that modulates activity of an Fc receptor, and a method of identifying a compound that modulates intracellular signaling of an Fc receptor. DNA constructs, cells, and kits relating to these assays are also disclosed.

Abstract: Disclosed are methods and compositions related to determining the status and mechanisms underlying long-term nonprogression of viral infections.

Abstract: A method (20) for selectively deleting messages received by a radio telephone (1). The method (20) includes detecting when the telephone (1) has moved from a previous coverage area to a current coverage area and selectively obtaining a set of coverage area specific messages (Mset) stored in a memory (16,18) associated with the telephone (1), the coverage area specific messages being from a set of messages received when the telephone was in the previous coverage area. The method (1) provides for and automatically deleting the coverage area specific messages from the memory (16,18) when the telephone (1) is in the current coverage area.